Arthroscopy tech assessment
This article was originally published in The Gray Sheet
CMS will determine by Jan. 8 the indications for which arthroscopic lavage and/or debridement are "reasonable and necessary" for treating osteoarthritis of the knee, based on a review of data published in The New England Journal of Medicine suggesting the procedures are no more effective than placebo (1"The Gray Sheet" Sept. 2, 2002, p. 6). In early December, the Veterans Administration plans to release an internal review of whether recent study findings warrant limited coverage of the procedure...
You may also be interested in...
The Veterans Administration plans to complete within the next 90 days an internal review of whether recent study findings warrant continued coverage of arthroscopic knee surgical procedures to alleviate pain and stiffness caused by osteoarthritis
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.